All In Biotech

Drug Trial Radar · NCT07056777

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

A Phase Ib/IIa Clinical Trial Evaluating the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Mar 25, 2025

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.

Conditions

  • Gastrointestinal Cancer

Interventions

  • DR30206Drug

    Subjects receive DR30206 intravenously

  • OxaliplatinDrug

    Subjects receive Oxaliplatin intravenously

  • CapecitabineDrug

    Subjects take Capecitabine orally

  • Calcium FolinateDrug

    Subjects receive Calcium Folinate intravenously

  • 5-FUDrug

    Subjects receive 5-FU by Intravenous Bolus

  • Irinotecan (CPT-11)Drug

    Subjects receive Irinotecan intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence of dose limiting toxicities (DLTs)Time frame: 21 days or 28 days following first dose according to the arms.
  2. Phase Ib: Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: From the first dose up to 90 days after the last dose or initiation of new anti-tumor treatment
  3. Phase Ib: Maximum tolerated dose(MTD)Time frame: 21 days or 28 days following first dose according to the arms.
  4. Phase Ib: Recommended phase 2 dose (RP2D)Time frame: 21 days or 28 days following first dose according to the arms.
  5. Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of other gastrointestinal tumorsTime frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first)
  6. Phase IIa: Objective response rate (ORR) (RECIST v1.1) of DR30206 in combination with standard therapy for the treatment of advanced or metastatic colorectal cancer.Time frame: the period from the date of initial medication to the objective recording of disease progression according to RECIST 1.1 standards or to the start of new anti-tumor treatment (whichever occurs first), assessed up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.